RU2244545C2 - Композиция пропофола с усиленным ингибированием микробов - Google Patents

Композиция пропофола с усиленным ингибированием микробов Download PDF

Info

Publication number
RU2244545C2
RU2244545C2 RU2002122394/15A RU2002122394A RU2244545C2 RU 2244545 C2 RU2244545 C2 RU 2244545C2 RU 2002122394/15 A RU2002122394/15 A RU 2002122394/15A RU 2002122394 A RU2002122394 A RU 2002122394A RU 2244545 C2 RU2244545 C2 RU 2244545C2
Authority
RU
Russia
Prior art keywords
composition
propofol
pharmaceutical composition
composition according
anesthetic pharmaceutical
Prior art date
Application number
RU2002122394/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2002122394A (ru
Inventor
Джек Йонгфэнг ЗХАНГ (US)
Джек Йонгфэнг ЗХАНГ
Джи Фэй ДИНГ (US)
Джи Фэй ДИНГ
Мэри Зи-Пинг ЛУО (US)
Мэри Зи-Пинг ЛУО
Original Assignee
Амфастар Фармацевтикалз Инкорпорейтед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амфастар Фармацевтикалз Инкорпорейтед filed Critical Амфастар Фармацевтикалз Инкорпорейтед
Publication of RU2002122394A publication Critical patent/RU2002122394A/ru
Application granted granted Critical
Publication of RU2244545C2 publication Critical patent/RU2244545C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2002122394/15A 2000-12-20 2001-07-16 Композиция пропофола с усиленным ингибированием микробов RU2244545C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/745,018 2000-12-20
US09/745,018 US6399087B1 (en) 2000-12-20 2000-12-20 Propofol formulation with enhanced microbial inhibition

Publications (2)

Publication Number Publication Date
RU2002122394A RU2002122394A (ru) 2004-03-20
RU2244545C2 true RU2244545C2 (ru) 2005-01-20

Family

ID=24994883

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002122394/15A RU2244545C2 (ru) 2000-12-20 2001-07-16 Композиция пропофола с усиленным ингибированием микробов

Country Status (11)

Country Link
US (1) US6399087B1 (https=)
EP (1) EP1250130A4 (https=)
JP (1) JP2004516265A (https=)
CN (1) CN1359677A (https=)
AU (1) AU7592501A (https=)
BR (1) BR0109769A (https=)
CA (1) CA2397990A1 (https=)
MX (1) MXPA02008097A (https=)
RU (1) RU2244545C2 (https=)
UA (1) UA73970C2 (https=)
WO (1) WO2002049631A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2290169C1 (ru) * 2005-06-23 2006-12-27 Открытое Акционерное Общество "Фаберлик" Косметическое и/или дерматологическое средство и антиоксидант

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
DE69912441T2 (de) 1998-08-19 2004-08-19 Skyepharma Canada Inc., Verdun Injizierbare wässerige propofoldispersionen
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
WO2003080027A1 (en) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
AU2003286725B2 (en) * 2002-10-29 2007-07-12 Transform Pharmaceuticals, Inc. Propofol with cysteine
CA2509365C (en) 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
US7468394B1 (en) * 2003-03-11 2008-12-23 Amphastar Pharmaceuticals, Inc. Sterile pharmaceutical composition and process for a solution of propofol emulsion having microbial growth retardation
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US8476010B2 (en) * 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
US8546453B2 (en) * 2003-08-14 2013-10-01 Rensheng Zhang Propofol compositions and methods for reducing pain associated with propofol injection
LT3311805T (lt) * 2005-08-31 2020-04-27 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus
EP3527202A1 (en) * 2005-08-31 2019-08-21 Abraxis BioScience, LLC Compositions and methods for preparation of poorly water soluble drugs with increased stability
CN101411685B (zh) * 2007-10-19 2011-04-20 上海医药工业研究院 一种静脉麻醉药2,6-二异丙基苯酚微乳组合物及其制备方法
PL2547323T3 (pl) 2010-03-17 2016-07-29 Novaliq Gmbh Kompozycja farmaceutyczna do leczenia podwyższonego ciśnienia wewnątrzgałkowego
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
ES2711760T3 (es) * 2011-01-04 2019-05-07 Novaliq Gmbh Emulsiones de aceite/agua que comprenden alcanos semifluorados
CN103501775A (zh) * 2011-03-04 2014-01-08 格吕伦塔尔有限公司 他喷他多的胃肠外给药
MX388963B (es) 2011-03-04 2025-03-20 Gruenenthal Gmbh Formulacion farmaceutica acuosa de tapentadol para administracion oral
JP2019142972A (ja) * 2011-03-04 2019-08-29 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口的投与
ES2910085T3 (es) 2011-03-04 2022-05-11 Gruenenthal Gmbh Composición farmacéutica acuosa semisólida que contiene tapentadol
DK2714010T3 (en) 2011-05-25 2017-06-12 Novaliq Gmbh TOPICAL PHARMACEUTICAL COMPOSITION BASED ON SEMIFLUORED ALKANES
JP2013001700A (ja) * 2011-06-21 2013-01-07 Fujifilm Corp プロポフォール含有水中油型エマルション組成物
JP5759804B2 (ja) * 2011-06-27 2015-08-05 富士フイルム株式会社 容器詰製剤
KR101989648B1 (ko) 2012-01-23 2019-06-14 노바리크 게엠베하 부분불소화 알칸에 기초한 안정화된 단백질 조성물
WO2013172999A1 (en) 2012-05-16 2013-11-21 Mewa Singh Pharmaceutical compositions for the delivery of substantially water-insoluble drugs
CN113679699B (zh) 2012-09-12 2022-10-28 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
AU2013314303B2 (en) 2012-09-12 2018-01-18 Novaliq Gmbh Semifluorinated alkane compositions
PT3024484T (pt) 2013-07-23 2018-10-24 Novaliq Gmbh Composições de anticorpo estabilizadas
PE20171651A1 (es) 2015-03-27 2017-11-13 Gruenenthal Chemie Formulacion estable para administracion parenteral de tapentadol
US10821087B2 (en) * 2015-07-24 2020-11-03 Neon Laboratories Limited Stabilized injectable emulsion of Propofol and Ketamine
WO2017031261A1 (en) 2015-08-20 2017-02-23 Mewa Singh Polyphenolic polymer to make water-insoluble molecules become water-soluble
US11154513B2 (en) 2015-09-30 2021-10-26 Novaliq Gmbh Semifluorinated compounds
CN110403923B (zh) 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
PT3442480T (pt) 2016-06-23 2019-12-23 Novaliq Gmbh Método de administração tópica
CA3036297C (en) 2016-09-22 2023-09-05 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
WO2018055101A1 (en) 2016-09-23 2018-03-29 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
EP3515412B1 (en) 2016-09-23 2025-04-23 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
EP4374851B1 (en) 2016-12-23 2026-04-15 Novaliq GmbH Ophthalmic composition for treatment of dry eye disease
CA3058097C (en) 2017-04-21 2024-01-02 Novaliq Gmbh Iodine compositions
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
KR20200128407A (ko) 2018-03-02 2020-11-12 노바리크 게엠베하 네비볼롤을 포함하는 약제학적 조성물
SG11202007860XA (en) 2018-03-28 2020-09-29 Novaliq Gmbh Pharmaceutical composition comprising timolol
CN112153970A (zh) 2018-04-27 2020-12-29 诺瓦利克有限责任公司 用于治疗青光眼的包含他氟前列素的眼用组合物
SG11202102820VA (en) 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2147432C1 (ru) * 1994-03-22 2000-04-20 Зенека Лимитед Эмульсии типа масло в воде, содержащие пропофол и эдетат
US6100302A (en) * 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69912441T2 (de) * 1998-08-19 2004-08-19 Skyepharma Canada Inc., Verdun Injizierbare wässerige propofoldispersionen
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2147432C1 (ru) * 1994-03-22 2000-04-20 Зенека Лимитед Эмульсии типа масло в воде, содержащие пропофол и эдетат
US6100302A (en) * 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2290169C1 (ru) * 2005-06-23 2006-12-27 Открытое Акционерное Общество "Фаберлик" Косметическое и/или дерматологическое средство и антиоксидант

Also Published As

Publication number Publication date
EP1250130A1 (en) 2002-10-23
JP2004516265A (ja) 2004-06-03
EP1250130A4 (en) 2006-03-15
RU2002122394A (ru) 2004-03-20
CA2397990A1 (en) 2002-06-27
WO2002049631A1 (en) 2002-06-27
MXPA02008097A (es) 2004-09-10
BR0109769A (pt) 2003-02-04
AU7592501A (en) 2002-07-01
UA73970C2 (en) 2005-10-17
US6399087B1 (en) 2002-06-04
CN1359677A (zh) 2002-07-24

Similar Documents

Publication Publication Date Title
RU2244545C2 (ru) Композиция пропофола с усиленным ингибированием микробов
KR100861820B1 (ko) 미생물 특성이 증진된 프로포폴 제제
EP1124536B1 (en) Propofol composition comprising pentetate
EP1052975B1 (en) Propofol composition containing sulfite
WO2010082092A1 (en) Propofol based anesthetic with preservative
CA2366799A1 (en) Propofol compositions containing preservative additives
AU2001275925B2 (en) Propofol formulation with enhanced microbial inhibition
US20070293586A1 (en) Novel propofol composition comprising ascorbic acid or pharmaceutically acceptable salts thereof
MXPA01004004A (en) Propofol composition comprising pentetate

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20070717